The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...

The new Alzheimer’s drug Kinsula is offering hope for patients by slowing down the progression of the disease. Neurologist Dr. Mauricio Concha administered the drug ...

If the European Medicines Agency takes an overly cautious approach to selecting specialists to advise on new medicines, ...

THURSDAY, Sept. 11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab ...

After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some ... a third of people living with dementia in the UK don’t get a diagnosis at all.

For Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease, these new drugs mark an ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

Leqembi, an Alzheimer's drug from Biogen and Eisai, faces hurdles with respect to reimbursement and diagnostic uncertainties, diagnostic test requirements and the need for regular brain scans, CNBC ...

As Gladstone Institutes commemorates World Alzheimer’s Month, Lennart Mucke, MD, discusses what’s next for Alzheimer’s ...